ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Rhea-AI Summary

ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on anaphylaxis prevention, has scheduled its fourth quarter and full year 2024 financial results conference call for March 20, 2025, at 8:30 a.m. ET.

The company will also participate in upcoming investor events including:

• Leerink Partners Global Healthcare Conference with a fireside chat on March 10, 2025
• 37th Annual Roth Conference with investor meetings on March 16-18, 2025

A webcast replay will be available for 30 days following the earnings call on the company's website under the Events & Presentations page.

Company to Host Conference Call on March 20 at 8:30 a.m. ET

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by registering for the event.

In addition, ARS Pharma Management will be participating in several upcoming investor conferences:

• Leerink Partners Global Healthcare Conference: fireside chat on March 10, 2025
• 37^th Annual Roth Conference: investor meetings on March 16-18, 2025

To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Investor Contacts:
Justin Chakma, ARS Pharmaceuticals
justinc@ars-pharma.com

Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668

FAQ

When will ARS Pharmaceuticals (SPRY) report Q4 and full year 2024 earnings?

ARS Pharmaceuticals will report Q4 and full year 2024 earnings on March 20, 2025, at 8:30 a.m. ET via conference call and webcast.

Which investor conferences will SPRY attend in March 2025?

SPRY will attend the Leerink Partners Global Healthcare Conference on March 10 and the 37th Annual Roth Conference during March 16-18, 2025.

How long will the SPRY Q4 2024 earnings webcast be available for replay?

The webcast replay will be available for 30 days following the earnings call on the company's website.

What is ARS Pharmaceuticals' (SPRY) main business focus?

ARS Pharmaceuticals focuses on empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis.